Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
NicOx and Pfizer reported more disappointing news related to their nitric-oxide donating prostaglandin analog candidate for glaucoma Aug. 25, noting the compound failed to meet its primary endpoint in a Japanese Phase II trial
You may also be interested in...
Pfizer Launches Phase II Trial For Experimental Glaucoma Treatment In Japan
Pfizer will expand the clinical development program for its experimental glaucoma treatment PF-03187207 by launching a Phase II trial in Japan, French partner NicOx announced Jan. 3
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).